Literature DB >> 34907083

Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.

Matias Autio1,2,3, Suvi-Katri Leivonen1,2,3, Oscar Brück4,5,6, Marja-Liisa Karjalainen-Lindsberg7, Teijo Pellinen8, Sirpa Leppä1,2,3.   

Abstract

PURPOSE: Tumor-infiltrating immune cells have prognostic significance and are attractive therapeutic targets. Yet, the clinical significance of their spatial organization and phenotype in diffuse large B-cell lymphoma (DLBCL) is unclear. EXPERIMENTAL
DESIGN: We characterized T cells, macrophages, and their spatial interactions by multiplex IHC (mIHC) in 178 patients with DLBCL and correlated the data with patient demographics and survival. We validated the findings on gene expression data from two external DLBCL cohorts comprising 633 patients.
RESULTS: Macrophage and T-cell contents divided the samples into T cell-inflamed (60%) and noninflamed (40%) subgroups. The T cell-inflamed lymphoma microenvironment (LME) was also rich in other immune cells, defining immune hot phenotype, which did not as such correlate with outcome. However, when we divided the patients according to T-cell and macrophage contents, LME characterized by high T-cell/low macrophage content or a corresponding gene signature was associated with superior survival [5-year overall survival (OS): 92.3% vs. 74.4%, P = 0.036; 5-year progression-free survival (PFS): 92.6% vs. 69.8%, P = 0.012]. High proportion of PD-L1- and TIM3-expressing CD163- macrophages in the T cell-inflamed LME defined a group of patients with poor outcome [OS: HR = 3.22, 95% confidence interval (CI), 1.63-6.37, Padj = 0.011; PFS: HR = 2.76, 95% CI, 1.44-5.28, Padj = 0.016]. Furthermore, PD-L1 and PD-1 were enriched on macrophages interacting with T cells.
CONCLUSIONS: Our data demonstrate that the interplay between macrophages and T cells in the DLBCL LME is immune checkpoint dependent and clinically meaningful. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34907083     DOI: 10.1158/1078-0432.CCR-21-3140

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  3 in total

1.  Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.

Authors:  Barbara Uhl; Katharina T Prochazka; Katrin Pansy; Kerstin Wenzl; Johanna Strobl; Claudia Baumgartner; Marta M Szmyra; James E Waha; Axel Wolf; Peter V Tomazic; Elisabeth Steinbauer; Maria Steinwender; Sabine Friedl; Marc Weniger; Ralf Küppers; Martin Pichler; Hildegard T Greinix; Georg Stary; Alan G Ramsay; Benedetta Apollonio; Julia Feichtinger; Christine Beham-Schmid; Peter Neumeister; Alexander J Deutsch
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

2.  Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma.

Authors:  Heli Vajavaara; Suvi-Katri Leivonen; Judit Jørgensen; Harald Holte; Sirpa Leppä
Journal:  EJHaem       Date:  2022-06-23

Review 3.  CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.

Authors:  Xiaomin Zhang; Lingling Zhu; Hui Zhang; Shanshan Chen; Yang Xiao
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.